Navigating tissue chips from development to dissemination: A pharmaceutical industry perspective
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Tissue chips are poised to deliver a paradigm shift in drug discovery. By emulating human physiology, these chips have the potential to increase the predictive power of preclinical modeling, which in turn will move the pharmaceutical industry closer to its aspiration of clinically relevant and ultimately animal-free drug discovery. Despite the tremendous science and innovation invested in these tissue chips, significant challenges remain to be addressed to enable their routine adoption into the industrial laboratory. This article describes the main steps that need to be taken and highlights key considerations in order to transform tissue chip technology from the hands of the innovators into those of the industrial scientists. Written by scientists from 13 pharmaceutical companies and partners at the National Institutes of Health, this article uniquely captures a consensus view on the progression strategy to facilitate and accelerate the adoption of this valuable technology. It concludes that success will be delivered by a partnership approach as well as a deep understanding of the context within which these chips will actually be used. Impact statement: The rapid pace of scientific innovation in the tissue chip (TC) field requires a cohesive partnership between innovators and end users. Near term uptake of these human-relevant platforms will fill gaps in current capabilities for assessing important properties of disposition, efficacy and safety liabilities. Similarly, these platforms could support mechanistic studies which aim to resolve challenges later in development (e.g. assessing the human relevance of a liability identified in animal studies). Building confidence that novel capabilities of TCs can address real world challenges while they themselves are being developed will accelerate their application in the discovery and development of innovative medicines. This article outlines a strategic roadmap to unite innovators and end users thus making implementation smooth and rapid. With the collective contributions from multiple international pharmaceutical companies and partners at National Institutes of Health, this article should serve as an invaluable resource to the multi-disciplinary field of TC development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Martignoni, M., Groothuis, G. M. M., & de Kanter, R. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.6.875 · Cited by 1,478
Organs-on-chips at the frontiers of drug discovery
Esch, E. W., Bahinski, A., & Huh, D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4539 · Cited by 1,185 · cited 1×
“We believe that TCs will enable a paradigm shift in drug discovery by increasing the predictive power of early preclinical modeling with their distinctive bioengineered features more accurately emulating human physiology.(2,3) In the United States, TC development has received considerable support from the National Ins…”
BackgroundA Human Disease Model of Drug Toxicity–Induced Pulmonary Edema in a Lung-on-a-Chip Microdevice
Huh, D., Leslie, D. C., Matthews, B. D., Fraser, J. P., Jurek, S., Hamilton, G. A., Thorneloe, K. S., McAlexander, M. A., & Ingber, D. E. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004249 · Cited by 993 · cited 1×
“TCs that would support mechanistic investigation of either pharmacology or toxicity are likely to be a popular initial context of use with published examples already available.(4) Combination with technologies such as iPSC and CRISPR cas9 offer unique opportunities to test functional consequences of making precise tar…”
BackgroundKim, H. J., Li, H., Collins, J. J., & Ingber, D. E. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522193112 · Cited by 922
Wang, G., McCain, M. L., Yang, L., He, A., Pasqualini, F. S., Agarwal, A., Yuan, H., Jiang, D., Zhang, D., Zangi, L., et al. (2014) · Nature Medicine · doi:10.1038/nm.3545 · Cited by 837
Animal models of human disease: challenges in enabling translation
McGonigle, P., & Ruggeri, B. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.08.006 · Cited by 610
Multi-Organ toxicity demonstration in a functional human in vitro system composed of four organs
Oleaga, C., Bernabini, C., Smith, A. S. T., Srinivasan, B., Jackson, M., McLamb, W., Platt, V., Bridges, R., Cai, Y., Santhanam, N., et al. (2016) · Scientific Reports · doi:10.1038/srep20030 · Cited by 442 · cited 1×
“Multi-organ systems are starting to be described in the literature.(9,10) Given the challenges of representing the influences of liver metabolism in single organ or 2D cell culture systems, linking liver to other important target organs of toxicity (e.”
BackgroundLaverty, H., Benson, C., Cartwright, E., Cross, M., Garland, C., Hammond, T., Holloway, C., McMahon, N., Milligan, J., Park, B., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01255.x · Cited by 363
Minimizing DILI risk in drug discovery — A screening tool for drug candidates
Schadt, S., Simon, S., Kustermann, S., Boess, F., McGinnis, C., Brink, A., Lieven, R., Fowler, S., Youdim, K., Ullah, M., et al. (2015) · Toxicology in Vitro · doi:10.1016/j.tiv.2015.09.019 · Cited by 89
Accurate prediction of human drug toxicity: a major challenge in drug development
Li, A. P. (2004) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2004.09.008 · Cited by 82
Cited by
Robotic fluidic coupling and interrogation of multiple vascularized organ chips
Novak, R., Ingram, M., Marquez, S., Das, D., Delahanty, A., Herland, A., Maoz, B. M., Jeanty, S. S. F., Somayaji, M. R., Burt, M., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0497-x · Cited by 427
Human biomimetic liver microphysiology systems in drug development and precision medicine
Gough, A., Soto-Gutierrez, A., Vernetti, L., Ebrahimkhani, M. R., Stern, A. M., & Taylor, D. L. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00386-1 · Cited by 117
Fabre, K., Berridge, B., Proctor, W. R., Ralston, S., Will, Y., Baran, S. W., Yoder, G., & Van Vleet, T. R. (2020) · Lab on a Chip · doi:10.1039/c9lc01168d · Cited by 116
Self-citationTowards in vitro models for reducing or replacing the use of animals in drug testing
Stresser, D. M., Kopec, A. K., Hewitt, P., Hardwick, R. N., Van Vleet, T. R., Mahalingaiah, P. K. S., O’Connell, D., Jenkins, G. J., David, R., Graham, J., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01154-7 · Cited by 94
Ekert, J. E., Deakyne, J., Pribul-Allen, P., Terry, R., Schofield, C., Jeong, C. G., Storey, J., Mohamet, L., Francis, J., Naidoo, A., et al. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220923332 · Cited by 68
Self-citation
Metadata
- Authors
- Ewart, L., Fabre, K., Chakilam, A., Dragan, Y., Duignan, D. B., Eswaraka, J., Gan, J., Guzzie-Peck, P., Otieno, M., Jeong, C. G., Keller, D. A., de Morais, S. M., Phillips, J. A., Proctor, W., Sura, R., Van Vleet, T., Watson, D., Will, Y., Tagle, D., & Berridge, B.
- Venue
- Experimental Biology and Medicine
- Publisher
- Frontiers Media SA
- Published
- 2017-06-16
- Volume
- 242
- Issue
- 16
- Pages
- 1579-1585
- ISSN
- 0071-3384 (ISSN-L)
- 1535-3702
- 1535-3699
- OpenAlex
- W2626436465
- Cited by
- 89
- References
- 10
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Navigating tissue chips from development to dissemination: A pharmaceutical industry perspective. https://app.cochat.ai/papers/10.1177/1535370217715441
- The paper
- Ewart, L., Fabre, K., Chakilam, A., Dragan, Y., Duignan, D. B., Eswaraka, J., Gan, J., Guzzie-Peck, P., Otieno, M., Jeong, C. G., Keller, D. A., de Morais, S. M., Phillips, J. A., Proctor, W., Sura, R., Van Vleet, T., Watson, D., Will, Y., Tagle, D., & Berridge, B. (2017). Navigating tissue chips from development to dissemination: A pharmaceutical industry perspective. Experimental Biology and Medicine. https://doi.org/10.1177/1535370217715441
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.